PS
FOLD

Principal Securities’s Amicus Therapeutics FOLD Stock Holding History

Principal Securities’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-958
Closed -$9.02K – 3759
2025
Q1 		$9.02K Hold
958
– – ﹤0.01% 2569
2024
Q4 		$9.02K Buy
958
+441
+85% +$4.58K ﹤0.01% 2564
2024
Q3 		$5.52K Sell
517
-15
-3% -$163 ﹤0.01% 2643
2024
Q2 		$5.28K Sell
532
-62
-10% -$636 ﹤0.01% 2622
2024
Q1 		$7K Buy
594
+130
+28% +$1.66K ﹤0.01% 2488
2023
Q4 		$6.58K Buy
+464
New +$5.27K ﹤0.01% 2424

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Principal Securities's FOLD Position: Q2 2025 in Review

Principal Securities sold out of Amicus Therapeutics (FOLD) in Q2 2025, closing a stake of 958 shares — an estimated $9.02K sold.

Principal Securities first reported a position in FOLD in Q4 2023 and held it in 6 quarters. The position peaked at $9.02K in Q1 2025. 272 funds tracked by Wall St. Rank hold FOLD as of Q2 2025.

  • Principal Securities reported no remaining Amicus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Principal Securities sold 958 Amicus Therapeutics shares in Q2 2025, an estimated $9.02K.
  • Principal Securities first reported a position in Amicus Therapeutics in Q4 2023 and held it in 6 quarters.
  • Principal Securities's Amicus Therapeutics position peaked at $9.02K in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2025.

Based on Principal Securities's 13F filing for Q2 2025, filed 11 Aug 2025.